Hypoxia-Inducible Factor-1 Mediates Activation of Cultured Vascular Endothelial Cells by Inducing Multiple Angiogenic Factors

Abstract— Hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of vascular endothelial growth factor (VEGF) and other hypoxia-responsive genes. Transgenic expression of a constitutively stable HIF-1&agr; mutant increases the number of vascular vessels without vascular leakage, tissue edema, or inflammation. This study aimed to investigate the molecular basis by which HIF-1 mediates the angiogenic response to hypoxia. In primary human endothelial cells, hypoxia, desferrioxamine, or infection with Ad2/HIF-1&agr;/VP16, an adenoviral vector encoding a constitutively stable hybrid form of HIF-1&agr;, increased the mRNA and protein levels of VEGF, angiopoietin-2 (Ang-2), and angiopoietin-4 (Ang-4). Infection with Ad2/CMVEV (a control vector expressing no transgene) had no effect. Angiopoietin-1 (Ang-1) expression was not detected in human endothelial cells. Ang-4 was also induced by hypoxia or Ad2/HIF-1&agr;/VP16 in human cardiac cells, whereas Ang-1 expression remained unchanged. Recombinant Ang-4 protein protected endothelial cells against serum starvation-induced apoptosis and increased cultured endothelial cell migration and tube formation. Ad2/HIF-1&agr;/VP16 stimulated endothelial cell proliferation and tube formation. Hypoxia- or Ad2/HIF-1&agr;/VP16-induced tube formation was significantly reduced by a Tie-2 inhibitor. These results suggest that HIF-1 mediates the angiogenic response to hypoxia by upregulating the expression of multiple angiogenic factors. Ang-4 can function similarly as Ang-1 and substitute for Ang-1 to participate in hypoxia-induced angiogenesis. Activation of the angiopoietin/Tie-2 system may play a role in the ability of HIF-1 to induce hypervascularity without excessive permeability.

[1]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[2]  S. McKnight,et al.  Building better vasculature. , 2001, Genes & development.

[3]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[4]  E. Goetzl,et al.  Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. , 2000, American journal of physiology. Cell physiology.

[5]  H. Blau,et al.  The well-tempered vessel , 2001, Nature Medicine.

[6]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[7]  B. Varnum,et al.  Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[8]  P. Carmeliet,et al.  VEGFR-1–Selective VEGF Homologue PlGF Is Arteriogenic: Evidence for a Monocyte-Mediated Mechanism , 2003, Circulation research.

[9]  M. Goldberg,et al.  Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1α , 2002 .

[10]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[11]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[12]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[13]  N. Maulik,et al.  Early effects of hypoxia/reoxygenation on VEGF, Ang-1, Ang-2 and their receptors in the rat myocardium: Implications for myocardial angiogenesis , 2000, Molecular and Cellular Biochemistry.

[14]  W. Kaelin How oxygen makes its presence felt. , 2002, Genes & development.

[15]  G. Yancopoulos,et al.  The angiopoietins: Yin and Yang in angiogenesis. , 1999, Current topics in microbiology and immunology.

[16]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[17]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[18]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[19]  K. Wagner,et al.  Tie2 Receptor Expression Is Stimulated by Hypoxia and Proinflammatory Cytokines in Human Endothelial Cells , 2000, Circulation research.

[20]  A. Woolf,et al.  Hypoxia up-regulates angiopoietin-2, a Tie-2 ligand, in mouse mesangial cells. , 2000, Kidney international.

[21]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.

[22]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[23]  J. Isner,et al.  Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. , 1998, Circulation.

[24]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[25]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[26]  K. Suzuma,et al.  Hypoxia and Vascular Endothelial Growth Factor Selectively Up-regulate Angiopoietin-2 in Bovine Microvascular Endothelial Cells* , 1999, The Journal of Biological Chemistry.

[27]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[28]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[29]  F. Larcher,et al.  VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development , 1998, Oncogene.

[30]  G. Garcı́a-Cardeña,et al.  Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[31]  S. Hussain,et al.  Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[32]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[33]  M. Goldberg,et al.  Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1&agr;/VP16 Hybrid Transcription Factor , 2000, Circulation.

[34]  K. Alitalo,et al.  Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. , 2001, Cardiovascular research.

[35]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[36]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[37]  J. M. Arbeit,et al.  Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. , 2001, Genes & development.

[38]  N. Copeland,et al.  Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Seng H. Cheng,et al.  Hypoxia Up-regulates Expression of Peroxisome Proliferator-activated Receptor γ Angiopoietin-related Gene (PGAR) in Cardiomyocytes: Role of Hypoxia Inducible Factor 1α , 2002 .

[40]  G. Krikun,et al.  Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. , 2000, Biochemical and biophysical research communications.

[41]  S. Mandriota,et al.  Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. , 1998, Circulation research.

[42]  S. Mandriota,et al.  Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. , 2000, The American journal of pathology.

[43]  Thomas N. Sato,et al.  Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Isner Myocardial gene therapy , 2002, Nature.

[45]  G. Semenza,et al.  Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[46]  K. Shyu,et al.  Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. , 2002, Cardiovascular research.

[47]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[48]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.